FDA approves Novo Nordisk's Sogroya(R) as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...
Shacknews

Weekend PC Download Deals for Feb. 27: Anno 117 free trial

Pay $6 or more to get Shady Part of Me and Curse of the Dead Gods. Pay $18 or more to also receive A Plague Tale: Innocence ...
WJFW

FDA approves Novo Nordisk's Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

Sogroya® (somapacitan-beco) is a once-weekly treatment option, offering an alternative to once-daily therapy, which may help ...